Full history for every metric is available with a Kvantra account
Exscientia plc (EXAI)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | - | 9 | 10 | 27 | 27 | 20 | 17 |
| Operating profit | £m | -176 | -168 | |||||
| Net profit | £m | - | -6 | -22 | -49 | -119 | -146 | -151 |
| EPS reported | £ | -1.18 | -1.20 | |||||
| Operating cashflow per share | £ | -0.95 | -0.95 | |||||
| Capex per share | £ | 0.21 | 0.21 | |||||
| FCF per share | £ | -1.16 | -1.16 | |||||
| Free cash flow | £m | -144 | -119 | |||||
| Net debt | £m | -361 | -244 | |||||
| Book value equity | £m | 359 | 255 | |||||
| Book value per share | £ | 2.89 | 2.02 | |||||
| Number of shares | m | 124.2 | 126.59 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.74 | 1.87 | |||||
| P/S LTM | x | 31.18 | 28.02 | |||||
| P/FCF LTM | x | -4.34 | -4.04 | |||||
| EV/EBITDA LTM | x | -2.66 | -1.73 | |||||
| EV/Sales LTM | x | 19.29 | 13.74 | |||||
| Earnings Yield LTM | % | -23.32% | -32.07% | |||||
| FCF Yield | % | -23.05% | -24.78% | |||||
| Quality | ||||||||
| ROE | % | -40.67% | -38.96% | |||||
| ROIC | % | -35.37% | -35.37% | |||||
| Operating margin | % | -876.56% | -876.56% | |||||
| Gross margin | % | -36.48% | -36.48% | |||||
| FCF/Sales | % | -718.46% | -718.46% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -26.24% | -30.22% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -7.62 | -6.38 | |||||
| Net Debt/EBITDA | x | 1.64 | 1.64 | |||||
| EBIT/Net interest | x | -164.95 | -164.95 | |||||
| Net debt/market cap | % | -57.65% | -50.98% | |||||
| Net debt/Equity | x | -1.01 | -0.95 | |||||
| Gross debt/equity | x | 0.05 | 0.07 | |||||
Company overview
Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Exscientia plc (EXAI)
Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free